Frequently rearranged in advanced T-cell lymphomas-1 (FRAT1) is a glycogen synthase kinase 3 β (GSK3β)-binding protein and belongs to the FRAT family. This protein contains a conserved GSK3β interacting domain. The FRAT1 gene is ubiquitously expressed and is mapped on the human chromosome at 10q24.1.
Anti-FRAT1 (C-terminal) specifically recognizes human and rat FRAT1.
Anti-FRAT1 (C-terminal) antibody produced in rabbit may be used in immunoblotting.
Frequently rearranged in advanced T-cell lymphomas-1 (FRAT1) protein plays a pivotal role in positively regulating the wingless-related integration site (Wnt)/β-catenin signaling pathway. This protein competes with axin for binding of glycogen synthase kinase 3 β (GSK3β), thus displacing GSK3β from the axin-β-catenin complex. The FRAT1 gene expression is upregulated in several human cancer lines primarily in gastric cancer. Overexpression of this gene is associated with esophageal squamous cell carcinoma (ESCC), ovarian, breast and cervical carcinoma. The FRAT1 gene expression is also observed in astrocytomas and human gliomas.
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Storage and Stability
For continuous use, store at 2–8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing, or storage in “frost-free” freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.
Unless otherwise stated in our catalog, our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.